ID   NCI-H460
AC   CVCL_0459
SY   NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460
DR   BTO; BTO:0002207
DR   CLO; CLO_0003601
DR   CLO; CLO_0008089
DR   EFO; EFO_0003044
DR   MCCL; MCC:0000356
DR   CLDB; cl1548
DR   cancercelllines; CVCL_0459
DR   AddexBio; C0016003/39
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-177
DR   BCRC; 60373
DR   BioSample; SAMN03471184
DR   BioSample; SAMN10987808
DR   CCRID; 1101HUM-PUMC000355
DR   CCRID; 1102HUM-NIFDC00086
DR   CCRID; 3101HUMTCHu205
DR   CCRID; 4201HUM-CCTCC00109
DR   Cell_Model_Passport; SIDM00144
DR   CGH-DB; 199-1
DR   CGH-DB; 9186-4
DR   ChEMBL-Cells; CHEMBL3307677
DR   ChEMBL-Targets; CHEMBL396
DR   CLS; 305020
DR   Cosmic; 722064
DR   Cosmic; 724876
DR   Cosmic; 755469
DR   Cosmic; 844595
DR   Cosmic; 875852
DR   Cosmic; 877263
DR   Cosmic; 877407
DR   Cosmic; 897508
DR   Cosmic; 905943
DR   Cosmic; 911996
DR   Cosmic; 931371
DR   Cosmic; 947356
DR   Cosmic; 980964
DR   Cosmic; 1006534
DR   Cosmic; 1017826
DR   Cosmic; 1028956
DR   Cosmic; 1032436
DR   Cosmic; 1044245
DR   Cosmic; 1047102
DR   Cosmic; 1089231
DR   Cosmic; 1092621
DR   Cosmic; 1146917
DR   Cosmic; 1154605
DR   Cosmic; 1152502
DR   Cosmic; 1188592
DR   Cosmic; 1219077
DR   Cosmic; 1239922
DR   Cosmic; 1305349
DR   Cosmic; 1312334
DR   Cosmic; 1434967
DR   Cosmic; 1436013
DR   Cosmic; 1477420
DR   Cosmic; 1802310
DR   Cosmic; 1870275
DR   Cosmic; 1945869
DR   Cosmic; 1995579
DR   Cosmic; 1998463
DR   Cosmic; 2042872
DR   Cosmic; 2058650
DR   Cosmic; 2125199
DR   Cosmic; 2433756
DR   Cosmic; 2560230
DR   Cosmic; 2630413
DR   Cosmic; 2664114
DR   Cosmic; 2772154
DR   Cosmic-CLP; 905943
DR   DepMap; ACH-000463
DR   DSMZ; ACC-737
DR   DSMZCellDive; ACC-737
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GDSC; 905943
DR   GEO; GSM2152
DR   GEO; GSM50216
DR   GEO; GSM50279
DR   GEO; GSM206493
DR   GEO; GSM253335
DR   GEO; GSM274737
DR   GEO; GSM274738
DR   GEO; GSM385522
DR   GEO; GSM385533
DR   GEO; GSM434334
DR   GEO; GSM513936
DR   GEO; GSM514322
DR   GEO; GSM743455
DR   GEO; GSM750809
DR   GEO; GSM784193
DR   GEO; GSM794288
DR   GEO; GSM799343
DR   GEO; GSM799406
DR   GEO; GSM827469
DR   GEO; GSM844652
DR   GEO; GSM844651
DR   GEO; GSM847076
DR   GEO; GSM887430
DR   GEO; GSM888510
DR   GEO; GSM1153414
DR   GEO; GSM1178473
DR   GEO; GSM1178474
DR   GEO; GSM1178475
DR   GEO; GSM1181352
DR   GEO; GSM1181361
DR   GEO; GSM1374746
DR   GEO; GSM1374747
DR   GEO; GSM1374748
DR   GEO; GSM1557134
DR   GEO; GSM2124676
DR   IARC_TP53; 21083
DR   IGRhCellID; NCI-H460%20GEO
DR   KCB; KCB 2010102YJ
DR   KCLB; 30177
DR   LiGeA; CCLE_338
DR   Lonza; 728
DR   PharmacoDB; NCIH460_1114_2019
DR   PRIDE; PXD005940
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0459
DR   PubChem_Cell_line; CVCL_0459
DR   Wikidata; Q54908057
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=2041050;
RX   PubMed=2388294;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=7718330;
RX   PubMed=8385084;
RX   PubMed=8626706;
RX   PubMed=8806092;
RX   PubMed=10358721;
RX   PubMed=10700174;
RX   PubMed=11030152;
RX   PubMed=11551417;
RX   PubMed=11583962;
RX   PubMed=12068308;
RX   PubMed=12794755;
RX   PubMed=15746151;
RX   PubMed=15748285;
RX   PubMed=15900046;
RX   PubMed=17088437;
RX   PubMed=17332333;
RX   PubMed=18083107;
RX   PubMed=19372543;
RX   PubMed=19472407;
RX   PubMed=19941903;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20510196;
RX   PubMed=20557307;
RX   PubMed=22068913;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22961666;
RX   PubMed=23381221;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24135919;
RX   PubMed=24279929;
RX   PubMed=24465237;
RX   PubMed=24670534;
RX   PubMed=25120651;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=33425914;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 33 hours (Note=In RPMI 1640 + 10% FBS), 60 hours (Note=In ACL-3), 42 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 19 hours (PubMed=7718330); 0.8 days (PubMed=11551417); 21.5 hours (PubMed=29681454); 18.39 +- 1.35 hours (PubMed=33425914); ~23 hours (DSMZ=ACC-737); 17.8 hours (NCI-DTP=NCI-H460).
CC   HLA typing: A*24,68; B*35,51; C*03,15; DQB1*03:01:01,05:01:01; DRB1*01,04 (PubMed=15748285).
CC   HLA typing: A*24:02,68:01; B*35:01,51:01; C*03:03,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (PubMed=12068308; PubMed=12794755; PubMed=17088437; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1311061; PubMed=15900046; PubMed=20557307).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=65.65%; European, South=32.24% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=19372543; PubMed=25877200; PubMed=33425914
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 13
ST   D12S391: 21
ST   D13S317: 13
ST   D16S539: 9
ST   D18S51: 13,15
ST   D19S433: 14
ST   D1S1656: 11,14.3
ST   D21S11: 30
ST   D22S1045: 17
ST   D2S1338: 17,25
ST   D2S441: 11,11.3
ST   D3S1358: 15,18
ST   D5S818: 9,10
ST   D7S820: 9,12
ST   D8S1179: 12
ST   DYS391: 11
ST   FGA: 21,23
ST   Penta D: 11,13
ST   Penta E: 5
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 46
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D.,
RA   Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
RX   PubMed=1563005;
RA   Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.;
RT   "Neuromedin B is present in lung cancer cell lines.";
RL   Cancer Res. 52:2732s-2736s(1992).
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31:230-237(1995).
RX   PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x;
RA   Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y.,
RA   Takahashi T., Ueda R.;
RT   "Alterations of integrin expression in human lung cancer.";
RL   Jpn. J. Cancer Res. 84:168-174(1993).
RX   PubMed=8626706; DOI=10.1074/jbc.271.19.11477;
RA   Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M.,
RA   Grimley C., Battey J., Mulshine J.L., Cuttitta F.;
RT   "Insulin-like growth factor expression in human cancer cell lines.";
RL   J. Biol. Chem. 271:11477-11483(1996).
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
RX   PubMed=11551417; DOI=10.1016/s0169-5002(01)00205-7;
RA   Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J.;
RT   "In vitro establishment of cis-diammine-dichloroplatinum(II) resistant
RT   lung cancer cell line and modulation of apoptotic gene expression as a
RT   mechanism of resistant phenotype.";
RL   Lung Cancer 33:221-228(2001).
RX   PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7;
RA   Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T.,
RA   Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H.,
RA   Fujii Y., Takahashi T.;
RT   "Persistent increase in chromosome instability in lung cancer:
RT   possible indirect involvement of p53 inactivation.";
RL   Am. J. Pathol. 159:1345-1352(2001).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=12794755; DOI=10.1002/ijc.11184;
RA   Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T.,
RA   Mitsudomi T.;
RT   "RASSF1A gene inactivation in non-small cell lung cancer and its
RT   clinical implication.";
RL   Int. J. Cancer 106:45-51(2003).
RX   PubMed=15746151; DOI=10.1093/hmg/ddi092;
RA   Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in
RT   non-small cell lung cancers.";
RL   Hum. Mol. Genet. 14:997-1007(2005).
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
RX   PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339;
RA   Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T.,
RA   Takada M., Fukuoka M., Nakagawa K.;
RT   "Differential constitutive activation of the epidermal growth factor
RT   receptor in non-small cell lung cancer cells bearing EGFR gene
RT   mutation and amplification.";
RL   Cancer Res. 67:2046-2053(2007).
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
RX   PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022;
RA   Karger A., Bettin B., Lenk M., Mettenleiter T.C.;
RT   "Rapid characterisation of cell cultures by matrix-assisted laser
RT   desorption/ionisation mass spectrometric typing.";
RL   J. Virol. Methods 164:116-121(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20510196; DOI=10.1016/j.ijrobp.2009.12.076;
RA   Lee Y.S., Oh J.-H., Yoon S., Kwon M.-S., Song C.-W., Kim K.-H.,
RA   Cho M.-J., Mollah M.L., Je Y.J., Kim Y.-D., Kim C.D., Lee J.-H.;
RT   "Differential gene expression profiles of radioresistant
RT   non-small-cell lung cancer cell lines established by fractionated
RT   irradiation: tumor protein p53-inducible protein 3 confers sensitivity
RT   to ionizing radiation.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 77:858-866(2010).
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
RX   PubMed=23381221; DOI=10.3892/or.2013.2266;
RA   Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K.,
RA   Ohba Y., Yamada T., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small
RT   cell lung cancer.";
RL   Oncol. Rep. 29:1308-1314(2013).
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
RX   PubMed=24135919; DOI=10.1038/ncomms3617;
RA   Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R.,
RA   Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G.,
RA   Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.;
RT   "Reconstructing targetable pathways in lung cancer by integrating
RT   diverse omics data.";
RL   Nat. Commun. 4:2617.1-2617.13(2013).
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
RX   PubMed=24465237; DOI=10.5808/GI.2013.11.4.245;
RA   Im C.-N., Kim B.M., Moon E.-Y., Hong D.-W., Park J.W., Hong S.H.;
RT   "Characterization of H460R, a radioresistant human lung cancer cell
RT   line, and involvement of syntrophin beta 2 (SNTB2) in
RT   radioresistance.";
RL   Genomics Inform. 11:245-253(2013).
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
RX   PubMed=25120651; DOI=10.3892/ol.2014.2234;
RA   Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K.,
RA   Shibata H., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation and silencing of IRF8 expression in non-small
RT   cell lung cancer.";
RL   Oncol. Lett. 8:1025-1030(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
RX   PubMed=30038707; DOI=10.18632/oncotarget.25642;
RA   Du L.-Q., Zhao Z.-Z., Suraokar M., Shelton S.S., Ma X.-Y., Hsiao T.-H.,
RA   Minna J.D., Wistuba I.I., Pertsemlidis A.;
RT   "LMO1 functions as an oncogene by regulating TTK expression and
RT   correlates with neuroendocrine differentiation of lung cancer.";
RL   Oncotarget 9:29601-29618(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=33425914; DOI=10.3389/fcell.2020.607275;
RA   Lei Z.-N., Teng Q.-X., Zhang W., Fan Y.-F., Wang J.-Q., Cai C.-Y.,
RA   Lu K.W., Yang D.-H., Wurpel J.N.D., Chen Z.-S.;
RT   "Establishment and characterization of a topotecan resistant non-small
RT   cell lung cancer NCI-H460/TPT10 cell line.";
RL   Front. Cell Dev. Biol. 8:607275.1-607275.10(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).